Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | SABCS 2022 key takeaways: optimizing treatment sequencing strategies

Kim Blenman • 7 Dec 2022
SABCS 2022
Breast Cancer Antibodies Durvalumab

Kim Blenman, PhD, MS, Yale School of Medicine, New Haven, CT, discusses the application of liquid biopsies, including with circulating tumor cells (CTCs), cytokines and autoantibody profiling, to monitor treatment response as well as treatment toxicity. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kim Blenman

1:28
Liquid biopsy to predict and monitor treatment response and toxicity
Kim Blenman • 7 Dec 2022
2:55
Systemic immune response to durvalumab concomitant with neoadjuvant chemotherapy in early stage TNCB
Kim Blenman • 7 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals